Product Images Xulane

View Photos of Packaging, Labels & Appearance

Figure 1: VTE Risk of Norelgestromin and Ethinyl Estradiol Transdermal System Relative to Combined Oral Contraceptives - image 01
Figure 5: Mean Serum Concentration-Time Profiles of NGMN Following Once-Daily Administration of an Oral Contraceptive for two cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for two cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 02
image 03
Figure 6: Mean Serum Concentration-Time Profiles of EE Following Once-Daily Administration of an Oral Contraceptive for two cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for two cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 04
Norelgestromin and Ethinyl Estradiol Structural Formulas - image 05
image 06
image 07
image 08
image 09
image 10
image 11
image 12
image 14
image 15
image 16
image 17
image 18
image 19
image 20
image 21
image 22
Label Image - lbl500901683

Product Label Images

The following 22 images provide visual information about the product associated with Xulane NDC 50090-1683 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: VTE Risk of Norelgestromin and Ethinyl Estradiol Transdermal System Relative to Combined Oral Contraceptives - image 01

This text provides information on different methods of birth control, including implants, injections, intrauterine devices, birth control pills, skin patches, vaginal rings with hormones, condoms, diaphragms, spermicide, withdrawal, and abstaining from sex on fertile days of the monthly cycle. It also discusses the varying number of pregnancies per 100 women in one year based on the birth control method used.*

Figure 5: Mean Serum Concentration-Time Profiles of NGMN Following Once-Daily Administration of an Oral Contraceptive for two cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for two cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 02

image 03

Figure 6: Mean Serum Concentration-Time Profiles of EE Following Once-Daily Administration of an Oral Contraceptive for two cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for two cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 04

Norelgestromin and Ethinyl Estradiol Structural Formulas - image 05

image 06

image 07

This is a chart outlining the ranges of blood clot occurrences per 10,000 woman-years based on different user categories (CHC user, Pregnant, Postpartum). It specifies that the data for pregnancy is based on actual duration of pregnancy in reference studies. The abbreviation "CHC" stands for combination hormonal contraception. The chart seems to provide information on the incidence rates of blood clots for different groups of women.*

image 08

image 09

image 10

image 11

image 12

image 14

image 15

This text provides information on postpartum contraception, specifically highlighting the use of combination hormonal contraception (CHC) for mothers 13 weeks postpartum. The data on pregnancy rates is based on actual pregnancy durations rather than a standard assumption of nine months. The text mentions a pregnancy rate of 7 to 27 per 10,000 women-years using this model.*

image 16

image 17

image 18

image 19

image 20

image 21

image 22

Label Image - lbl500901683

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents